

HERCULES TECHNOLOGY GROWTH CAPITAL INC
Form 10-Q
May 07, 2015

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For The Quarterly Period Ended March 31, 2015

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 814-00702

HERCULES TECHNOLOGY GROWTH

CAPITAL, INC.

(Exact Name of Registrant as Specified in its Charter)

Maryland
(State or Jurisdiction of

Incorporation or Organization)

743113410
(IRS Employer

Identification No.)
94301

400 Hamilton Ave., Suite 310 (Zip Code)

Palo Alto, California

(Address of Principal Executive Offices)

(650) 289-3060

(Registrant's Telephone Number, Including Area Code)

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter periods that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this Chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer Accelerated filer

Non-accelerated filer Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

On May 4, 2015, there were 72,584,695 shares outstanding of the Registrant's common stock, \$0.001 par value.

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

FORM 10-Q TABLE OF CONTENTS

<u>PART I. FINANCIAL INFORMATION</u>	3
Item 1. <u>Consolidated Financial Statements</u>	3
<u>Consolidated Statement of Assets and Liabilities as of March 31, 2015 (unaudited) and December 31, 2014</u>	3
<u>Consolidated Statement of Operations for the three month periods ended March 31, 2015 and 2014 (unaudited)</u>	5
<u>Consolidated Statement of Changes in Net Assets for the three month periods ended March 31, 2015 and 2014 (unaudited)</u>	6
<u>Consolidated Statement of Cash Flows for the three month periods ended March 31, 2015 and 2014 (unaudited)</u>	7
<u>Consolidated Schedule of Investments as of March 31, 2015 (unaudited)</u>	8
<u>Consolidated Schedule of Investments as of December 31, 2014</u>	22
<u>Notes to Consolidated Financial Statements (unaudited)</u>	36
Item 2. <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	64
Item 3. <u>Quantitative and Qualitative Disclosures About Market Risk</u>	98
Item 4. <u>Controls and Procedures</u>	99
<u>PART II. OTHER INFORMATION</u>	100
<u>Legal Proceedings</u>	100

Item 1.

Item 1A. Risk Factors 100

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 101

Item 3. Defaults Upon Senior Securities 101

Item 4. Mine Safety Disclosures 101

Item 5. Other Information 101

Item 6. Exhibits 102

SIGNATURES 103

PART I: FINANCIAL INFORMATION

In this Quarterly Report, the “Company,” “Hercules,” “we,” “us” and “our” refer to Hercules Technology Growth Capital, Inc. and its wholly owned subsidiaries and its affiliated securitization trusts unless the context otherwise requires.

ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS
HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES

(unaudited)

(dollars in thousands, except per share data)

	March 31, 2015	December 31, 2014
Assets		
Investments:		
Non-control/Non-affiliate investments (cost of \$1,154,801 and \$1,019,799, respectively)	\$ 1,150,639	\$ 1,012,738
Affiliate investments (cost of \$16,007 and \$15,538, respectively)	10,782	7,999
Total investments, at value (cost of \$1,170,808 and \$1,035,337, respectively)	1,161,421	1,020,737
Cash and cash equivalents	171,756	227,116
Restricted cash	21,949	12,660
Interest receivable	9,102	9,453
Other assets	22,860	29,257
Total assets	\$ 1,387,088	\$ 1,299,223
Liabilities		
Accounts payable and accrued liabilities	\$ 9,320	\$ 14,101
Long-term Liabilities (Convertible Senior Notes)	17,375	17,345
2017 Asset-Backed Notes	4,203	16,049
2021 Asset-Backed Notes	129,300	129,300
2019 Notes	170,364	170,364
2024 Notes	103,000	103,000
Long-term SBA Debentures	190,200	190,200
Total liabilities	\$ 623,762	\$ 640,359
Net assets consist of:		
Common stock, par value	73	65
Capital in excess of par value	760,034	657,233
Unrealized depreciation on investments	(11,462)	(17,076)
Accumulated realized gains on investments	17,391	14,079
Undistributed net investment income (Distributions in excess of net investment income)	(2,710)	4,563
Total net assets	\$ 763,326	\$ 658,864
Total liabilities and net assets	\$ 1,387,088	\$ 1,299,223

Shares of common stock outstanding (\$0.001 par value, 100,000,000 authorized)	72,891	64,715
Net asset value per share	\$10.47	\$10.18

See notes to consolidated financial statements.

3

The following table presents the assets and liabilities of our consolidated securitization trusts for the asset-backed notes (see Note 4), which are variable interest entities (“VIE”). The assets of our securitization VIEs can only be used to settle obligations of our consolidated securitization VIEs, these liabilities are only the obligations of our consolidated securitization VIEs, and the creditors (or beneficial interest holders) do not have recourse to our general credit. These assets and liabilities are included in the Consolidated Statement of Assets and Liabilities above.

(Dollars in thousands)	March 31, 2015	December 31, 2014
Assets		
Restricted Cash	\$21,949	\$12,660
Total investments, at value (cost of \$261,304 and \$296,314, respectively)	262,394	291,464
Total assets	\$284,343	\$304,124
Liabilities		
Asset-Backed Notes	\$133,503	\$145,349
Total liabilities	\$133,503	\$145,349

See notes to consolidated financial statements.

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED STATEMENT OF OPERATIONS

(unaudited)

(in thousands, except per share data)

	For the Three Months Ended March 31,	
	2015	2014
Investment income:		
Interest income		
Non-Control/Non-Affiliate investments	\$ 30,459	\$ 29,382
Affiliate investments	100	1,464
Total interest income	30,559	30,846
Fees		
Non-Control/Non-Affiliate investments	1,934	4,913
Affiliate investments	1	11
Total fees	1,935	4,924
Total investment income	32,494	35,770
Operating expenses:		
Interest	7,854	7,148
Loan fees	1,513	2,076
General and administrative	3,618	2,461
Employee Compensation:		
Compensation and benefits	3,796	4,221
Stock-based compensation	2,719	1,560
Total employee compensation	6,515	5,781
Total operating expenses	19,500	17,466
Loss on debt extinguishment (Long-term Liabilities - Convertible Senior Notes)	(1)	—
Net investment income	12,993	18,304
Net realized gain on investments		
Non-Control/Non-Affiliate investments	3,312	4,872
Total net realized gain on investments	3,312	4,872
Net increase in unrealized appreciation (depreciation) on investments		
Non-Control/Non-Affiliate investments	3,301	(1,038)
Affiliate investments	2,313	47
Total net unrealized appreciation (depreciation) on investments	5,614	(991)
Total net realized and unrealized gain (loss)	8,926	3,881
Net increase in net assets resulting from operations	\$ 21,919	\$ 22,185
Net investment income before investment gains and losses per common share:		
Basic	\$ 0.20	\$ 0.30
Change in net assets per common share:		

Edgar Filing: HERCULES TECHNOLOGY GROWTH CAPITAL INC - Form 10-Q

Basic	\$0.33	\$0.36
Diluted	\$0.33	\$0.35
Weighted average shares outstanding		
Basic	63,783	60,870
Diluted	64,163	62,695
Dividends declared per common share:		
Basic	\$0.31	\$0.31

See notes to consolidated financial statements.

5

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED STATEMENT OF CHANGES IN NET ASSETS

(unaudited)

(dollars and shares in thousands)

	Common Shares	Stock Par Value	Capital in excess of par value	Unrealized Appreciation (Depreciation on Investments)	Accumulated Realized Gains (Losses) on Investments	Undistributed net investment income/ (Distributions in excess of Investment income)	Provision for Income Taxes on Investment Gains	Net Assets
Balance at December 31, 2013	61,837	\$62	\$ 656,594	\$ 3,598	\$ (15,240)	\$ 5,335	\$ (342)	\$ 650,007
Net increase (decrease) in net assets								
resulting from operations	—	—	—	(991)	4,872	18,304	—	22,185
Issuance of common stock due to								
stock option exercises	62	—	727	—	—	—	—	727
Retired shares from net issuance	(48)	—	(748)	—	—	—	—	(748)
Retired shares for restricted stock								
vesting	(120)	—	(1,724)	—	—	—	—	(1,724)
Issuance of common stock as								
stock dividend	29	—	440	—	—	—	—	440
Dividends distributed	—	—	—	—	—	(19,165)	—	(19,165)
Stock-based compensation	—	—	1,580	—	—	—	—	1,580
Balance at March 31, 2014	61,760	\$62	\$ 656,869	\$ 2,607	\$ (10,368)	\$ 4,474	\$ (342)	\$ 653,302
Balance at December 31, 2014	64,715	\$65	\$ 657,233	\$ (17,076)	\$ 14,079	\$ 4,905	\$ (342)	\$ 658,864
Net increase (decrease) in net assets	—	—	—	5,614	3,312	12,993	—	21,919

resulting from operations								
Public offering, net of offering expenses	7,591	8	100,084	—	—	—	—	100,092
Issuance of common stock due to								
stock option exercises	34	—	406	—	—	—	—	406
Retired shares from net issuance	(27)	—	(401)	—	—	—	—	(401)
Issuance of common stock under								
restricted stock plan	580	—	—	—	—	—	—	—
Retired shares for restricted stock								
vesting	(42)	—	(591)	—	—	—	—	(591)
Issuance of common stock as								
stock dividend	40	—	562	—	—	—	—	562
Dividends distributed	—	—	—	—	—	(20,266)	—	(20,266)
Stock-based compensation	—	—	2,741	—	—	—	—	2,741
Balance at March 31, 2015	72,891	\$73	\$760,034	\$ (11,462)	\$ 17,391	\$ (2,368)	\$ (342)	\$763,326

See notes to consolidated financial statements.

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED STATEMENT OF CASH FLOWS

(unaudited)

(dollars in thousands)

	For the Three Months Ended March 31,	
	2015	2014
Cash flows from operating activities:		
Net increase in net assets resulting from operations	\$21,919	\$22,185
Adjustments to reconcile net increase in net assets resulting from operations to net cash provided by (used in) operating activities:		
Purchase of investments	(209,387)	(113,887)
Principal and fee payments received on investments	75,368	135,008
Proceeds from the sale of investments	7,001	7,598
Net unrealized depreciation (appreciation) on investments	(5,614)	991
Net realized gain on investments	(3,312)	(4,872)
Accretion of paid-in-kind principal	(665)	(659)
Accretion of loan discounts	(1,356)	(3,378)
Accretion of loan discount on Convertible Senior Notes	62	271
Loss on debt extinguishment (Long-term Liabilities - Convertible Senior Notes)	1	—
Payment of loan discount on Convertible Senior Notes	(2)	—
Accretion of loan exit fees	(2,767)	(2,411)
Change in deferred loan origination revenue	1,540	(457)
Unearned fees related to unfunded commitments	527	(125)
Amortization of debt fees and issuance costs	1,288	1,913
Depreciation	58	54
Stock-based compensation and amortization of restricted stock grants	2,741	1,579
Change in operating assets and liabilities:		
Interest and fees receivable	351	786
Prepaid expenses and other assets	2,674	(3,401)
Accounts payable	(504)	(41)
Accrued liabilities	(3,978)	(5,307)
Net cash provided by (used in) operating activities	(114,055)	35,847
Cash flows from investing activities:		
Purchases of capital equipment	(42)	(4)
Reduction of (investment in) restricted cash	(9,289)	1,487
Net cash provided by (used in) investing activities	(9,331)	1,483
Cash flows from financing activities:		
Issuance of common stock, net	100,092	(135)
Issuance (retirement) of employee shares	(586)	(1,738)

Edgar Filing: HERCULES TECHNOLOGY GROWTH CAPITAL INC - Form 10-Q

Dividends paid	(19,704)	(18,725)
Repayments of 2017 Asset-Backed Notes	(11,846)	(25,775)
Repayments of Long-Term SBA Debentures	—	(34,800)
Cash Paid for redemption of Convertible Senior Notes	(30)	—
Fees paid for credit facilities and debentures	100	13
Net cash provided by (used in) financing activities	68,026	(81,160)
Net decrease in cash and cash equivalents	(55,360)	(43,830)
Cash and cash equivalents at beginning of period	227,116	268,368
Cash and cash equivalents at end of period	\$171,756	\$224,538
Supplemental non-cash investing and financing activities:		
Dividends Reinvested	\$562	\$440
Paid-in-kind Principal	\$1,356	\$1,207

See notes to consolidated financial statements.

7

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2015

(unaudited)

(dollars in thousands)

Portfolio Company	Sub-Industry	Type of Investment ⁽¹⁾	Maturity Date	Interest Rate and Floor	Principal Amount	Cost ⁽²⁾	Value ⁽³⁾	
Debt Investment								
Communications & Networking								
1-5 Years Maturity								
OpenPeak, Inc. ⁽¹⁰⁾⁽¹²⁾	Communications & Networking	Senior Secured	April 2017	Interest rate PRIME + 8.75% or Floor rate of 12.00%	\$11,680	\$11,864	\$11,981	
KeyCross, Inc. ⁽¹²⁾⁽¹³⁾	Communications & Networking	Senior Secured	January 2018	Interest rate PRIME + 9.70% or Floor rate of 12.95%	\$22,000	21,551	17,775	
Subtotal: 1-5 Years Maturity						33,415	29,756	
Subtotal: Communications & Networking (3.90%)*						33,415	29,756	
Consumer & Business Products								
1-5 Years Maturity								
Antenna79 (p.k.a. Pong Research Corporation) ⁽¹¹⁾⁽¹²⁾⁽¹³⁾	Consumer & Business Products	Senior Secured	December 2017	Interest rate PRIME + 6.75% or Floor rate of 10.00%, PIK Interest 2.50%	\$4,869	4,798	4,944	
	Consumer & Business Products	Senior Secured	June 2016	Interest rate PRIME + 7.75% or Floor rate of 11.00%	\$183	183	182	
Total Antenna79 (p.k.a. Pong Research Corporation)						\$5,052	4,981	5,126
Fluc, Inc. ⁽⁸⁾	Consumer & Business Products	Convertible Senior Note	March 2017	Interest rate FIXED 4.00%	\$100	100	100	
IronPlanet, Inc. ⁽¹²⁾	Consumer & Business Products	Senior Secured	November 2017	Interest rate PRIME + 6.20% or Floor rate of 9.45%	\$37,500	36,911	36,911	
The Neat Company ⁽¹¹⁾⁽¹²⁾⁽¹³⁾	Consumer & Business	Senior Secured	September 2017	Interest rate PRIME + 7.75%	\$20,111	19,624	19,536	

Edgar Filing: HERCULES TECHNOLOGY GROWTH CAPITAL INC - Form 10-Q

Products			or Floor rate of 11.00%, PIK Interest 1.00%			
Subtotal: 1-5 Years Maturity					61,616	61,673
Subtotal: Consumer & Business Products (8.08%)*					61,616	61,673
Drug Delivery						
1-5 Years Maturity						
AcelRx Pharmaceuticals, Inc. ⁽⁹⁾⁽¹⁰⁾⁽¹²⁾⁽¹³⁾	Drug Delivery	Senior Secured	October 2017	Interest rate PRIME + 3.85% or Floor rate of 9.10%	\$25,000	25,020 25,261
Agile Therapeutics, Inc. ⁽¹²⁾	Drug Delivery	Senior Secured	December 2018	Interest rate PRIME + 5.75% or Floor rate of 9.00%	\$16,500	15,904 15,904
ABIND Therapeutics, Inc. ⁽¹²⁾⁽¹³⁾	Drug Delivery	Senior Secured	July 2018	Interest rate PRIME + 5.10% or Floor rate of 8.35%	\$15,000	14,787 14,051
BioQuiddity Incorporated ⁽¹²⁾	Drug Delivery	Senior Secured	May 2018	Interest rate PRIME + 8.00% or Floor rate of 11.25%	\$7,500	7,490 7,490
Celator Pharmaceuticals, Inc. ⁽¹⁰⁾⁽¹²⁾	Drug Delivery	Senior Secured	June 2018	Interest rate PRIME + 6.50% or Floor rate of 9.75%	\$15,000	14,846 14,886
Celsion Corporation ⁽¹⁰⁾⁽¹²⁾	Drug Delivery	Senior Secured	June 2017	Interest rate PRIME + 8.00% or Floor rate of 11.25%	\$9,122	9,071 9,243
Dance Biopharm, Inc. ⁽¹²⁾⁽¹³⁾	Drug Delivery	Senior Secured	November 2017	Interest rate PRIME + 7.40% or Floor rate of 10.65%	\$3,616	3,610 3,614
Edge Therapeutics, Inc. ⁽¹²⁾	Drug Delivery	Senior Secured	March 2018	Interest rate PRIME + 5.95% or Floor rate of 10.45%	\$6,000	5,894 5,820
Egalet Corporation ⁽¹²⁾	Drug Delivery	Senior Secured	July 2018	Interest rate PRIME + 6.15% or Floor rate of 9.40%	\$15,000	14,764 14,764
Neos Therapeutics, Inc. ⁽¹²⁾⁽¹³⁾	Drug Delivery	Senior Secured	October 2017	Interest rate PRIME + 7.25% or Floor rate of 10.50%	\$10,000	9,847 9,947
	Drug Delivery	Senior Secured	October 2017	Interest rate FIXED 9.00%	\$10,000	10,000 9,874
Total Neos Therapeutics, Inc.					\$20,000	19,847 19,821
Zosano Pharma, Inc. ⁽¹⁰⁾⁽¹²⁾	Drug Delivery	Senior Secured	June 2017	Interest rate PRIME + 6.80% or Floor rate of 12.05%	\$3,652	3,580 3,601
Subtotal: 1-5 Years Maturity						134,813 134,455
Subtotal: Drug Delivery (17.61%)*						134,813 134,455

See notes to consolidated financial statements.

8

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2015

(unaudited)

(dollars in thousands)

Portfolio Company	Sub-Industry	Type of Investment ⁽¹⁾	Maturity Date	Interest Rate and Floor	Principal Amount	Cost ⁽²⁾	Value
Under 1 Year Maturity							
Pharmaceuticals, ⁽¹⁰⁾⁽¹²⁾⁽¹³⁾	Drug Discovery & Development	Senior Secured	December 2015	Interest rate PRIME + 7.15% or Floor rate of 11.90%	\$8,854	\$8,854	\$8,854
ert Pharmaceuticals, Inc. ⁽¹⁰⁾	Drug Discovery & Development	Senior Secured	October 2015	Interest rate PRIME + 3.25% or Floor rate of 8.50%	\$5,086	5,070	5,070
ed, Incorporated ⁽¹⁰⁾⁽¹²⁾	Drug Discovery & Development	Senior Secured	January 2016	Interest rate PRIME + 4.75% or Floor rate of 9.25%	\$25,000	24,958	24,958
Total: Under 1 Year Maturity						38,882	38,882
1-5 Years Maturity							
IA Biologics, Inc. ⁽¹⁰⁾⁽¹¹⁾⁽¹²⁾	Drug Discovery & Development	Senior Secured	December 2017	Interest rate PRIME + 3.00% or Floor rate of 8.75%, PIK Interest 1.95%	\$15,225	15,011	15,225
Pharmaceuticals, ⁽¹⁰⁾⁽¹²⁾⁽¹³⁾	Drug Discovery & Development	Senior Secured	January 2018	Interest rate PRIME + 6.65% or Floor rate of 11.90%	\$10,000	9,846	9,911
don Corporation ⁽¹²⁾⁽¹³⁾	Drug Discovery & Development	Senior Secured	February 2018	Interest rate PRIME + 5.00% or Floor rate of 8.25%	\$10,000	10,106	10,106
pra, Inc. ⁽¹⁰⁾⁽¹²⁾	Drug Discovery & Development	Senior Secured	April 2018	Interest rate PRIME + 6.30% or Floor rate of 9.55%	\$18,000	18,035	18,225
cor Inc. ⁽¹²⁾	Drug Discovery & Development	Senior Secured	August 2017	Interest rate PRIME + 4.70% or Floor rate of 7.95%	\$7,500	7,411	7,380
ean Pharma Inc. ⁽¹²⁾	Drug Discovery & Development	Senior Secured	July 2018	Interest rate PRIME + 4.05% or Floor rate of 7.30%	\$15,000	14,718	14,718
eland BioLabs, Inc. ⁽¹²⁾⁽¹³⁾			January 2017	Interest rate LIBOR + 6.20%	\$1,702	1,956	1,911

Edgar Filing: HERCULES TECHNOLOGY GROWTH CAPITAL INC - Form 10-Q

	Drug Discovery & Development	Senior Secured		or Floor rate of 10.45%			
Cell Therapeutics, Inc.) ⁽¹⁰⁾⁽¹²⁾	Drug Discovery & Development	Senior Secured	October 2016	Interest rate PRIME + 8.00%			
				or Floor rate of 11.25%	\$8,117	8,638	8,611
	Drug Discovery & Development	Senior Secured	October 2016	Interest rate PRIME + 6.75%			
				or Floor rate of 10.00%	\$4,030	4,110	4,095
	Drug Discovery & Development	Senior Secured	October 2016	Interest rate PRIME + 8.00%			
				or Floor rate of 11.25%	\$4,030	4,110	4,095
CTI BioPharma Corp. (p.k.a. Cell Therapeutics, Inc.) Vax Technologies ⁽⁹⁾⁽¹²⁾					\$16,177	16,858	16,858
	Drug Discovery & Development	Senior Secured	July 2018	Interest rate PRIME + 6.50%			
				or Floor rate of 9.75%	\$10,000	9,983	9,983
Biopharmaceuticals, ⁽²⁾	Drug Discovery & Development	Senior Secured	April 2018	Interest rate PRIME + 4.70%			
				or Floor rate of 7.95%	\$7,500	7,345	7,465
cea Biosciences, Inc. ⁽¹⁰⁾⁽¹²⁾	Drug Discovery & Development	Senior Secured	July 2018	Interest rate PRIME + 4.00%			
				or Floor rate of 7.25%	\$12,000	11,881	11,881
nta Therapeutics ⁽¹²⁾	Drug Discovery & Development	Senior Secured	June 2018	Interest rate PRIME + 5.00%			
				or Floor rate of 8.25%	\$20,000	19,429	19,429
netics, Inc. (p.k.a. Lithera, ⁽²⁾⁽¹³⁾	Drug Discovery & Development	Senior Secured	January 2018	Interest rate PRIME + 5.75%			
				or Floor rate of 9.00%	\$10,000	9,806	9,826
imack Pharmaceuticals, ⁽²⁾	Drug Discovery & Development	Senior Secured	November 2018	Interest rate PRIME + 7.30%			
				or Floor rate of 10.55%	\$40,000	40,515	40,515
alstem, Inc. ⁽¹²⁾⁽¹³⁾	Drug Discovery & Development	Senior Secured	April 2017	Interest rate PRIME + 6.75%			
				or Floor rate of 10.00%	\$9,489	9,389	9,389
ure B.V. ⁽⁴⁾⁽⁹⁾⁽¹⁰⁾⁽¹²⁾	Drug Discovery & Development	Senior Secured	June 2018	Interest rate PRIME + 5.00%			
				or Floor rate of 10.25%	\$20,000	19,878	20,278
IA Corporation ⁽⁹⁾⁽¹²⁾⁽¹³⁾	Drug Discovery & Development	Senior Secured	September 2018	Interest rate PRIME + 6.15%			
				or Floor rate of 9.40%	\$20,000	19,536	19,536
Total: 1-5 Years Maturity						241,703	242,703
Total: Drug Discovery & Development							
(7%)*						280,585	281,585
Electronics & Computer Hardware							
Years Maturity							
s Technologies, Inc. ⁽⁷⁾⁽¹¹⁾	Electronics & Computer Hardware	Senior Secured	October 2016	Interest rate LIBOR + 8.75%	\$267	180	—
				or Floor rate of 12.00%,			

PIK Interest 4.00%

Total: 1-5 Years Maturity	180	—
Total: Electronics & Computer Hardware (%)*	180	—

See notes to consolidated financial statements.

9

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2015

(unaudited)

(dollars in thousands)

Portfolio Company	Sub-Industry	Type of Investment ⁽¹⁾	Maturity Date	Interest Rate and Floor	Principal Amount	Cost ⁽²⁾	Value ⁽³⁾
Energy Technology							
Under 1 Year Maturity							
Fluidic, Inc. ⁽¹⁰⁾⁽¹²⁾	Energy Technology	Senior Secured	March 2016	Interest rate PRIME + 8.00%			
				or Floor rate of 11.25%	\$2,981	\$3,081	\$3,081
Stion Corporation ⁽⁵⁾⁽¹²⁾	Energy Technology	Senior Secured	March 2016	Interest rate PRIME + 8.75%			
				or Floor rate of 12.00%	\$3,462	3,462	1,600
TAS Energy, Inc. ⁽¹⁰⁾⁽¹²⁾	Energy Technology	Senior Secured	December 2015	Interest rate PRIME + 7.75%			
				or Floor rate of 11.00%	\$6,149	6,242	6,242
Subtotal: Under 1 Year Maturity						12,785	10,923
1-5 Years Maturity							
Agrivida, Inc. ⁽¹²⁾⁽¹³⁾	Energy Technology	Senior Secured	December 2016	Interest rate PRIME + 6.75%			
				or Floor rate of 10.00%	\$4,921	5,016	4,969
American Superconductor Corporation ⁽¹⁰⁾⁽¹²⁾	Energy Technology	Senior Secured	November 2016	Interest rate PRIME + 7.25%			
				or Floor rate of 11.00%	\$6,667	6,964	6,843
	Energy Technology	Senior Secured	March 2017	Interest rate PRIME + 7.75%			
				or Floor rate of 11.00%	\$1,500	1,460	1,446
Total American Superconductor Corporation					\$8,167	8,424	8,289
Amyris, Inc. ⁽⁹⁾⁽¹²⁾	Energy Technology	Senior Secured	February 2017	Interest rate PRIME + 6.25%			
				or Floor rate of 9.50%	\$25,000	25,000	25,458
	Energy Technology	Senior Secured	February 2017	Interest rate PRIME + 5.25%			
				or Floor rate of 8.50%	\$5,000	5,000	5,092
Total Amyris, Inc.					\$30,000	30,000	30,550
Modumetal, Inc. ⁽¹²⁾	Energy Technology	Senior Secured	March 2017	Interest rate PRIME + 10.45%			
				or Floor rate of 13.70%	\$2,708	2,760	2,744

Edgar Filing: HERCULES TECHNOLOGY GROWTH CAPITAL INC - Form 10-Q

Polyera Corporation ⁽¹²⁾⁽¹³⁾	Energy Technology	Senior Secured	June 2016	Interest rate PRIME + 6.75%			
				or Floor rate of 10.00%	\$3,080	3,272	3,258
	Energy Technology	Senior Secured	April 2018	Interest rate PRIME + 6.70%			
				or Floor rate of 9.95%	\$3,000	2,904	2,904
Total Polyera Corporation					\$6,080	6,176	6,162
Sungevity Development, LLC	Energy Technology	Senior Secured	October 2017	Interest rate PRIME + 3.70%			
				or Floor rate 6.95%	\$25,000	23,963	23,963
	Energy Technology	Senior Secured	April 2016	Interest rate PRIME + 3.70%			
				or Floor rate 6.95%	\$16,017	16,017	16,017
Total Sungevity Development, LLC					\$41,017	39,980	39,980
Subtotal: 1-5 Years Maturity						92,356	92,694
Subtotal: Energy Technology (13.57%)*						105,141	103,617
Healthcare Services, Other							
1-5 Years Maturity							
Chromadex Corporation ⁽¹²⁾⁽¹³⁾	Healthcare Services, Other	Senior Secured	April 2018	Interest rate PRIME + 6.10%			
				or Floor rate of 9.35%	\$2,500	2,427	2,446
InstaMed Communications, LLC ⁽¹²⁾⁽¹³⁾	Healthcare Services, Other	Senior Secured	March 2018	Interest rate PRIME + 6.75%			
				or Floor rate of 10.00%	\$5,000	5,061	5,011
Subtotal: 1-5 Years Maturity						7,488	7,457
Subtotal: Healthcare Services, Other (0.98%)*						7,488	7,457
Information Services							
Under 1 Year Maturity							
Eccentex Corporation ⁽¹⁰⁾⁽¹²⁾	Information Services	Senior Secured	May 2015	Interest rate PRIME + 7.00%			
				or Floor rate of 10.25%	\$84	99	99
Subtotal: Under 1 Year Maturity						99	99
1-5 Years Maturity							
INMOBI Inc. ⁽⁴⁾⁽⁹⁾⁽¹¹⁾⁽¹²⁾	Information Services	Senior Secured	December 2016	Interest rate PRIME + 7.00%			
				or Floor rate of 10.25%	\$14,612	14,612	14,612
	Information Services	Senior Secured	December 2017	Interest rate PRIME + 5.75%			
				or Floor rate of 9.00%, PIK Interest 2.50%	\$15,107	15,003	15,003
Total INMOBI Inc.					\$29,719	29,615	29,615
InXpo, Inc. ⁽¹²⁾⁽¹³⁾	Information Services	Senior Secured	October 2016	Interest rate PRIME + 7.75%	\$1,800	1,828	1,819

or Floor rate of 10.75%

Subtotal: 1-5 Years Maturity	31,443	31,434
Subtotal: Information Services (4.13%)*	31,542	31,533

See notes to consolidated financial statements.

10

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2015

(unaudited)

(dollars in thousands)

Portfolio Company	Sub-Industry	Type of Investment ⁽¹⁾	Maturity Date	Interest Rate and Floor	Principal Amount	Cost ⁽²⁾	Value ⁽³⁾
Internet Consumer & Business Services							
Under 1 Year Maturity							
Education Dynamics, LLC ⁽¹¹⁾⁽¹³⁾	Internet Consumer & Business Services	Senior Secured	March 2016	Interest rate LIBOR + 12.50% or Floor rate of 12.50%, PIK Interest 1.50%	\$20,642	\$20,629	\$20,629
Magazelle, Inc. ⁽¹¹⁾⁽¹³⁾	Internet Consumer & Business Services	Senior Secured	December 2015	Interest rate PRIME + 6.50% or Floor rate of 9.75%	\$407	407	407
NetPlenish ⁽⁷⁾⁽⁸⁾⁽¹³⁾	Internet Consumer & Business Services	Convertible Senior Note	April 2015	Interest rate FIXED 10.00%	\$65	65	—
	Internet Consumer & Business Services	Senior Secured	September 2015	Interest rate FIXED 10.00%	\$381	373	—
Total NetPlenish					\$446	438	—
Tectura Corporation ⁽⁷⁾⁽¹¹⁾⁽¹⁴⁾	Internet Consumer & Business Services	Senior Secured	May 2014	Interest rate LIBOR + 10.00% or Floor rate of 13.00%	\$563	563	144
	Internet Consumer & Business Services	Senior Secured	May 2014	Interest rate LIBOR + 10.00% or Floor rate of 13.00%	\$5,000	5,000	1,276
	Internet Consumer & Business Services	Senior Secured	May 2014	Interest rate LIBOR + 10.00% or Floor rate of 13.00%	\$6,468	6,468	1,652
	Internet Consumer & Business Services	Senior Secured	May 2014	Interest rate LIBOR + 8.00% or Floor rate of 11.00%, PIK Interest 1.00%	\$9,070	9,070	2,317
Total Tectura Corporation					\$21,101	21,101	5,389
Subtotal: Under 1 Year Maturity						42,575	26,425
1-5 Years Maturity							

Edgar Filing: HERCULES TECHNOLOGY GROWTH CAPITAL INC - Form 10-Q

azelle, Inc. ⁽¹¹⁾⁽¹³⁾	Internet Consumer & Business Services	Senior Secured	July 2017	Interest rate PRIME + 7.00% or Floor rate of 10.25%, PIK Interest 2.50%	\$13,797	13,551	13,643	
ust Fabulous, Inc. ⁽¹⁰⁾⁽¹²⁾	Internet Consumer & Business Services	Senior Secured	February 2017	Interest rate PRIME + 8.25% or Floor rate of 11.50%	\$15,000	14,638	14,938	
ightspeed POS, Inc. ⁽⁴⁾⁽⁹⁾⁽¹⁰⁾	Internet Consumer & Business Services	Senior Secured	May 2018	Interest rate PRIME + 3.25% or Floor rate of 6.50%	\$2,000	1,987	2,000	
Reply! Inc. ⁽⁷⁾⁽¹¹⁾⁽¹²⁾	Internet Consumer & Business Services	Senior Secured	March 2019	Interest rate PRIME + 4.25% or Floor rate of 7.50%	\$6,321	5,952	3,212	
	Internet Consumer & Business Services	Senior Secured	March 2019	PIK Interest 2.00%	\$6,321	6,321	3,411	
total Reply! Inc.					\$12,642	12,273	6,623	
apjoy, Inc. ⁽¹²⁾	Internet Consumer & Business Services	Senior Secured	July 2018	Interest rate PRIME + 6.50% or Floor rate of 9.75%	\$20,000	19,496	19,415	
aveMarket, Inc. ⁽¹²⁾	Internet Consumer & Business Services	Senior Secured	March 2017	Interest rate PRIME + 6.50% or Floor rate of 9.75%	\$268	271	277	
Subtotal: 1-5 Years Maturity							62,216	56,896
Subtotal: Internet Consumer & Business Services (10.92%)*							104,791	83,321
Media/Content/Info								
Under 1 Year Maturity								
oom Media Group, Inc. ⁽¹⁰⁾⁽¹¹⁾	Media/Content/Info	Senior Secured	December 2015	Interest rate PRIME + 5.25% or Floor rate of 8.50%	\$5,060	5,060	5,060	
	Media/Content/Info	Senior Secured	December 2015	Interest rate PRIME + 7.25% or Floor rate of 10.50%, PIK Interest 3.75%	\$2,024	1,998	1,998	
Total Zoom Media Group, Inc.						\$7,084	7,058	7,058
Subtotal: Under 1 Year Maturity							7,058	7,058
1-5 Years Maturity								
hapsody International, Inc. ⁽¹⁰⁾⁽¹¹⁾⁽¹³⁾	Media/Content/Info	Senior Secured	April 2018	Interest rate PRIME + 5.25% or Floor rate of 9.00%, PIK interest of 1.50%	\$20,281	19,882	19,699	
Subtotal: 1-5 Years Maturity							19,882	19,699
Subtotal: Media/Content/Info (3.51%)*							26,940	26,757

See notes to consolidated financial statements.

11

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2015

(unaudited)

(dollars in thousands)

Portfolio Company	Sub-Industry	Type of Investment ⁽¹⁾	Maturity Date	Interest Rate and Floor	Principal Amount	Cost ⁽²⁾	Value ⁽³⁾
Medical Devices & Equipment							
Under 1 Year Maturity							
Home Dialysis Plus, Inc. ⁽¹⁰⁾⁽¹²⁾	Medical Devices & Equipment	Senior Secured	September 2015	Interest rate FIXED 8.00%	\$500	\$500	\$500
Medrobotics Corporation ⁽¹²⁾⁽¹³⁾	Medical Devices & Equipment	Senior Secured	March 2016	Interest rate PRIME + 7.85% or Floor rate of 11.10%	\$2,175	2,287	2,287
Subtotal: Under 1 Year Maturity						2,787	2,787
1-5 Years Maturity							
Amedica Corporation ⁽⁸⁾⁽¹²⁾⁽¹³⁾	Medical Devices & Equipment	Senior Secured	January 2018	Interest rate PRIME + 7.70% or Floor rate of 10.95%	\$20,000	19,912	20,153
Aspire Bariatrics, Inc. ⁽¹²⁾⁽¹³⁾	Medical Devices & Equipment	Senior Secured	April 2018	Interest rate PRIME + 6.00% or Floor rate of 9.25%	\$4,000	3,590	3,590
Avedro, Inc. ⁽¹²⁾⁽¹³⁾	Medical Devices & Equipment	Senior Secured	June 2018	Interest rate PRIME + 6.00% or Floor rate of 9.25%	\$12,500	12,096	11,998
Flowonix Medical Incorporated ⁽¹²⁾	Medical Devices & Equipment	Senior Secured	May 2018	Interest rate PRIME + 5.25% or Floor rate of 10.00%	\$15,000	14,768	14,768
Gamma Medica, Inc. ⁽¹⁰⁾⁽¹²⁾	Medical Devices & Equipment	Senior Secured	January 2018	Interest rate PRIME + 6.50% or Floor rate of 9.75%	\$4,000	3,907	3,885
Home Dialysis Plus, Inc. ⁽¹⁰⁾⁽¹²⁾	Medical Devices & Equipment	Senior Secured	October 2017	Interest rate PRIME + 6.35% or Floor rate of 9.60%	\$15,000	14,829	14,693
InspireMD, Inc. ⁽⁴⁾⁽⁹⁾⁽¹²⁾	Medical Devices & Equipment	Senior Secured	February 2017	Interest rate PRIME + 7.25% or Floor rate of 10.50%	\$7,901	8,065	8,029
nContact Surgical, Inc. ⁽¹²⁾⁽¹³⁾	Medical Devices & Equipment	Senior Secured	November 2018	Interest rate PRIME + 9.25% or Floor rate of 9.25%	\$10,000	9,783	9,783

Edgar Filing: HERCULES TECHNOLOGY GROWTH CAPITAL INC - Form 10-Q

Quanterix Corporation ⁽¹⁰⁾⁽¹²⁾	Medical Devices & Equipment	Senior Secured	February 2018	Interest rate PRIME + 2.75% or Floor rate of 8.00%	\$ 10,000	9,829	9,873
SonaCare Medical, LLC (p.k.a. US HIFU, LLC) ⁽¹⁰⁾⁽¹²⁾	Medical Devices & Equipment	Senior Secured	April 2016	Interest rate PRIME + 7.75% or Floor rate of 11.00%	\$ 875	1,231	1,171
SynergEyes, Inc. ⁽¹²⁾⁽¹³⁾	Medical Devices & Equipment	Senior Secured	January 2018	Interest rate PRIME + 7.75% or Floor rate of 11.00%	\$ 5,000	5,087	5,056
ViewRay, Inc. ⁽¹¹⁾⁽¹³⁾	Medical Devices & Equipment	Senior Secured	June 2017	Interest rate PRIME + 7.00% or Floor rate of 10.25%, PIK Interest 1.50%	\$ 13,949	13,701	13,790
Subtotal: 1-5 Years Maturity						116,798	116,789
Subtotal: Medical Devices & Equipment (15.67%)*						119,585	119,576
Semiconductors							
1-5 Years Maturity							
Avnera Corporation ⁽¹⁰⁾⁽¹²⁾	Semiconductors	Senior Secured	April 2017	Interest rate PRIME + 5.75% or Floor rate of 9.00%	\$ 5,000	5,004	5,016
Subtotal: 1-5 Years Maturity						5,004	5,016
Subtotal: Semiconductors (0.66%)*						5,004	5,016

See notes to consolidated financial statements.

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2015

(unaudited)

(dollars in thousands)

Portfolio Company	Sub-Industry	Type of Investment ⁽¹⁾	Maturity Date	Interest Rate and Floor	Principal Amount	Cost ⁽²⁾	Value
Under 1 Year Maturity							
Cloud Corporation ⁽¹²⁾⁽¹³⁾	Software	Senior Secured	July 2015	Interest rate PRIME + 1.40%			
				or Floor rate of 4.65%	\$3,000	\$3,000	\$3,000
ox, Inc. ⁽¹²⁾⁽¹³⁾	Software	Senior Secured	July 2015	Interest rate PRIME + 6.75%			
				or Floor rate of 10.00%	\$2,000	2,000	2,000
	Software	Senior Secured	August 2015	Interest rate PRIME + 8.75%			
				or Floor rate of 12.00%	\$3,000	2,991	2,991
Clickfox, Inc.					\$5,000	4,991	4,991
e Posse, Inc. ⁽¹²⁾⁽¹³⁾	Software	Senior Secured	June 2015	Interest rate PRIME + 2.00%			
				or Floor rate of 5.25%	\$1,000	1,000	1,000
Total: Under 1 Year Maturity							
						8,991	8,991
1 to 3 Years Maturity							
Cloud Corporation ⁽¹²⁾⁽¹³⁾	Software	Senior Secured	December 2017	Interest rate PRIME + 3.25%			
				or Floor rate of 6.50%	\$208	208	208
	Software	Senior Secured	July 2017	Interest rate PRIME + 5.50%			
				or Floor rate of 8.75%	\$10,000	9,885	9,885
	Software	Senior Secured	January 2018	Interest rate PRIME + 1.70%			
				or Floor rate of 4.95%	\$3,000	2,950	2,950
CareCloud Corporation					\$13,208	13,043	12,993
ox, Inc. ⁽¹²⁾⁽¹³⁾	Software	Senior Secured	March 2018	Interest rate PRIME + 8.25%			
				or Floor rate of 11.50%	\$6,000	5,889	5,889
, Inc. ⁽¹²⁾	Software	Senior Secured	March 2018	Interest rate PRIME + 4.60%			
				or Floor rate of 7.85%	\$9,000	8,894	8,894
Start Games, Inc.	Software	Senior Secured	October 2016	Interest rate PRIME + 8.25%	\$1,356	1,353	1,353

Edgar Filing: HERCULES TECHNOLOGY GROWTH CAPITAL INC - Form 10-Q

Knowledge Adventure, Inc.) (13)				or Floor rate of 11.50%, PIK Interest 6.50%			
	Software	Senior Secured	March 2018	Interest rate PRIME + 8.25%			
				or Floor rate of 11.50%, PIK Interest 6.50%	\$11,255	11,330	11,330
JumpStart Games, Inc. Knowledge Adventure, Inc.) ge Systems, Inc.(13)	Software	Senior Secured	February 2017	Interest rate PRIME + 2.75%	\$12,611	12,683	12,683
				or Floor rate of 6.00%	\$1,118	1,118	1,118
	Software	Senior Secured	February 2019	Interest rate PRIME + 7.25%			
				or Floor rate of 10.50%	\$17,500	16,996	16,996
Message Systems, Inc. e Posse, Inc.(12)(13)	Software	Senior Secured	December 2016	Interest rate PRIME + 7.50%	\$18,618	18,114	18,114
				or Floor rate of 10.75%	\$2,615	2,632	2,632
Geosolutions, Inc.(12)(13)	Software	Senior Secured	May 2016	Interest rate PRIME + 5.75%			
				or Floor rate of 10.50%	\$1,947	2,084	2,084
us, Inc.(12)(13)	Software	Senior Secured	June 2017	Interest rate PRIME + 5.25%			
				or Floor rate of 8.50%	\$1,500	1,514	1,514
, Inc.(12)(13)	Software	Senior Secured	February 2018	Interest rate PRIME + 2.25%			
				or Floor rate of 5.50%	\$3,500	3,372	3,372
	Software	Senior Secured	February 2018	Interest rate PRIME + 4.75%			
				or Floor rate of 8.00%	\$15,000	14,446	14,446
Soasta, Inc. a, Inc.(12)(13)	Software	Senior Secured	July 2017	Interest rate PRIME + 7.00%	\$18,500	17,818	17,818
				or Floor rate of 10.25%	\$5,029	5,006	5,006
View Systems, Inc.(11)(12)	Software	Senior Secured	December 2017	Interest rate PRIME + 6.00%			
				or Floor rate of 9.25%, PIK Interest 3.00%	\$10,074	9,861	9,861
commerce, Inc.(12)(13)	Software	Senior Secured	August 2016	Interest rate PRIME + 2.25%			
				or Floor Rate of 6.50%	\$4,811	4,811	4,811
	Software	Senior Secured	February 2018	Interest rate PRIME + 6.00%			
				or Floor Rate of 10.25%	\$7,000	6,723	6,723
Touchcommerce, Inc. al: 1-5 Years Maturity al: Software (15.44%)*					\$11,811	11,534	11,534
						109,072	109,072
						118,063	118,063

See notes to consolidated financial statements.

13

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2015

(unaudited)

(dollars in thousands)

Portfolio Company	Sub-Industry	Type of Investment ⁽¹⁾	Maturity Date	Interest Rate and Floor	Principal Amount	Cost ⁽²⁾	Value ⁽³⁾
Specialty Pharmaceuticals							
Under 1 Year Maturity							
Stranford Pharmaceuticals, LC ⁽¹⁰⁾⁽¹¹⁾⁽¹²⁾⁽¹³⁾	Specialty Pharmaceuticals	Senior Secured	August 2015	Interest rate LIBOR + 8.25% or Floor rate of 9.50%	\$2,000	\$2,000	\$2,000
Subtotal: Under 1 Year Maturity						2,000	2,000
1-5 Years Maturity							
Alimera Sciences, Inc. ⁽¹⁰⁾	Specialty Pharmaceuticals	Senior Secured	May 2018	Interest rate PRIME + 7.65% or Floor rate of 10.90%	\$35,000	34,225	33,856
Stranford Pharmaceuticals, LC ⁽¹⁰⁾⁽¹¹⁾⁽¹²⁾⁽¹³⁾	Specialty Pharmaceuticals	Senior Secured	February 2017	Interest rate LIBOR + 9.55% or Floor rate of 10.80%, PIK Interest 1.35%	\$14,101	14,125	14,206
Subtotal: 1-5 Years Maturity						48,350	48,062
Subtotal: Specialty Pharmaceuticals (5.56%)*						50,350	50,062
Surgical Devices							
Under 1 Year Maturity							
Transmedics, Inc. ⁽¹⁰⁾⁽¹²⁾	Surgical Devices	Senior Secured	November 2015	Interest rate FIXED 12.95%	\$5,519	5,473	5,473
Subtotal: Under 1 Year Maturity						5,473	5,473
Subtotal: Surgical Devices (0.72%)*						5,473	5,473
Total Debt Investments (138.61%)*						1,084,986	1,058,032

See notes to consolidated financial statements.

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2015

(unaudited)

(dollars in thousands)

Portfolio Company	Sub-Industry	Type of Investment ⁽¹⁾	Series	Shares	Cost ⁽²⁾	Value ⁽³⁾
Equity Investments						
Biotechnology Tools						
NuGEN Technologies, Inc. ⁽¹³⁾	Biotechnology Tools	Equity	Preferred Series C	189,394	\$500	\$535
Subtotal: Biotechnology Tools (0.07%)*					500	535
Communications & Networking						
GlowPoint, Inc. ⁽³⁾	Communications & Networking	Equity	Common Stock	114,192	102	104
Peerless Network, Inc.	Communications & Networking	Equity	Preferred Series A	1,000,000	1,000	6,247
Subtotal: Communications & Networking (0.83%)*					1,102	6,351
Consumer & Business Products						
Market Force Information, Inc.	Consumer & Business Products	Equity	Preferred Series B-1	187,970	500	3
	Consumer & Business Products	Equity	Common Stock	480,261	—	237
Total Market Force Information, Inc.				668,231	500	240
Subtotal: Consumer & Business Products (0.03%)*					500	240
Diagnostic						
Singulex, Inc.	Diagnostic	Equity	Common Stock	937,998	750	643
Subtotal: Diagnostic (0.08%)*					750	643
Drug Delivery						
AcelRx Pharmaceuticals, Inc. ⁽³⁾⁽⁹⁾⁽¹³⁾	Drug Delivery	Equity	Common Stock	54,240	108	209
	Drug Delivery	Equity		20,000	9	—

Edgar Filing: HERCULES TECHNOLOGY GROWTH CAPITAL INC - Form 10-Q

Merrion Pharmaceuticals, Plc (3)(4)(9)			Common Stock			
Neos Therapeutics, Inc.	Drug Delivery	Equity	Preferred Series C	300,000	1,500	1,856
Subtotal: Drug Delivery (0.27%)*					1,617	2,065

Drug Discovery & Development

Aveo Pharmaceuticals, Inc. (3)(9)(13)	Drug Discovery & Development	Equity	Common Stock	167,864	842	243
Cerecor Inc.	Drug Discovery & Development	Equity	Preferred Series B	3,334,445	1,000	762
Cerulean Pharma Inc. (3)	Drug Discovery & Development	Equity	Common Stock	135,501	1,000	1,222
Dicerna Pharmaceuticals, Inc. (3) (13)	Drug Discovery & Development	Equity	Common Stock	142,858	1,000	3,433
Epirus Biopharmaceuticals, Inc. (3)	Drug Discovery & Development	Equity	Common Stock	200,000	1,000	1,790
Genocea Biosciences, Inc. (3)	Drug Discovery & Development	Equity	Common Stock	223,463	2,000	2,650
Inotek Pharmaceuticals Corporation (3)	Drug Discovery & Development	Equity	Common Stock	3,778	1,500	20
Insmmed, Incorporated (3)	Drug Discovery & Development	Equity	Common Stock	70,771	1,000	1,322
Paratek Pharmaceutcals, Inc. (p.k.a. Transcept Pharmaceuticals, Inc.) (3)	Drug Discovery & Development	Equity	Common Stock	31,580	1,744	977
Subtotal: Drug Discovery & Development (1.63%)*					11,086	12,419

Electronics & Computer Hardware

Identiv, Inc. (3)	Electronics & Computer Hardware	Equity	Common Stock	6,700	34	57
Subtotal: Electronics & Computer Hardware (0.01%)*					34	57

Energy Technology

Glori Energy, Inc. (3)	Energy Technology	Equity	Common Stock	18,208	165	39
SCIEnergy, Inc.	Energy Technology	Equity	Preferred Series 1	385,000	761	24
Subtotal: Energy Technology (0.01%)*					926	63

Information Services

Good Technology Corporation (p.k.a. Visto Corporation) (13)	Information Services	Equity	Common Stock	500,000	603	646
Subtotal: Information Services (0.08%)*					603	646

Internet Consumer & Business Services

Edgar Filing: HERCULES TECHNOLOGY GROWTH CAPITAL INC - Form 10-Q

Blurb, Inc. ⁽¹³⁾	Internet Consumer & Business Services	Equity	Preferred Series B	220,653	175	279
Lightspeed POS, Inc. ⁽⁴⁾⁽⁹⁾	Internet Consumer & Business Services	Equity	Preferred Series C	23,003	250	274
Oportun (p.k.a. Progress Financial)	Internet Consumer & Business Services	Equity	Preferred Series G	218,351	250	402
	Internet Consumer & Business Services	Equity	Preferred Series H	87,802	250	252
Total Oportun (p.k.a. Progress Financial)				306,153	500	654
Philotic, Inc.	Internet Consumer & Business Services	Equity	Common Stock	9,023	93	—
RazorGator Interactive Group, Inc.	Internet Consumer & Business Services	Equity	Preferred Series AA	34,783	15	30
Taptera, Inc.	Internet Consumer & Business Services	Equity	Preferred Series B	454,545	150	176
Subtotal: Internet Consumer & Business Services (0.19%)*					1,183	1,413

See notes to consolidated financial statements.

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2015

(unaudited)

(dollars in thousands)

Portfolio Company	Sub-Industry	Type of Investment ⁽¹⁾	Series	Shares	Cost ⁽²⁾	Value ⁽³⁾
Medical Devices & Equipment						
Flowonix Medical Incorporated	Medical Devices & Equipment	Equity	Preferred Series E	221,893	\$1,500	\$1,794
Gelesis, Inc. ⁽⁵⁾⁽¹³⁾	Medical Devices & Equipment	Equity	Preferred Series A-1	674,208	425	785
	Medical Devices & Equipment	Equity	Preferred Series A-2	675,676	500	737
	Medical Devices & Equipment	Equity	Common Stock	698,862	—	714
Total Gelesis, Inc.				2,048,746	925	2,236
Medrobotics Corporation ⁽¹³⁾	Medical Devices & Equipment	Equity	Preferred Series E	136,798	250	162
	Medical Devices & Equipment	Equity	Preferred Series F	73,971	155	173
Total Medrobotics Corporation				210,769	405	335
Novasys Medical, Inc.	Medical Devices & Equipment	Equity	Preferred Series D-1	4,118,444	1,000	—
Optiscan Biomedical, Corp. ⁽⁵⁾⁽¹³⁾	Medical Devices & Equipment	Equity	Preferred Series B	6,185,567	3,000	539
	Medical Devices & Equipment	Equity	Preferred Series C	1,927,309	655	162
	Medical Devices & Equipment	Equity	Preferred Series D	55,103,923	5,257	5,789
Total Optiscan Biomedical, Corp.				63,216,799	8,912	6,490
Oraya Therapeutics, Inc.	Medical Devices & Equipment	Equity	Preferred Series 1	1,086,969	500	429
Subtotal: Medical Devices & Equipment (1.48%)*					13,242	11,284
Software						
Atrenta, Inc.	Software	Equity	Preferred Series C	1,196,845	986	2,045
Atrenta, Inc.	Software	Equity	Preferred Series D	635,513	508	1,231

Edgar Filing: HERCULES TECHNOLOGY GROWTH CAPITAL INC - Form 10-Q

Total Atrenta, Inc.				1,832,358	1,494	3,276
Box, Inc. ⁽³⁾ ⁽¹³⁾	Software	Equity	Common Stock	1,464,747	5,818	28,930
CapLinked, Inc.	Software	Equity	Preferred Series A-3	53,614	51	81
ForeScout Technologies, Inc.	Software	Equity	Preferred Series D	319,099	398	564
	Software	Equity	Preferred Series E	80,587	131	146
Total ForeScout Technologies, Inc.				399,686	529	710
HighRoads, Inc.	Software	Equity	Preferred Series B	190,170	307	343
WildTangent, Inc. ⁽¹³⁾	Software	Equity	Preferred Series 3	100,000	402	237
Subtotal: Software (4.40%)*					8,601	33,577
Specialty Pharmaceuticals						
QuatRx Pharmaceuticals Company	Specialty Pharmaceuticals	Equity	Preferred Series E	241,829	750	—
	Specialty Pharmaceuticals	Equity	Preferred Series E-1	26,955	—	—
	Specialty Pharmaceuticals	Equity	Preferred Series G	4,667,636	—	—
Total QuatRx Pharmaceuticals Company				4,936,420	750	—
Subtotal: Specialty Pharmaceuticals (0.00%)*					750	—
Surgical Devices						
Gynesonics, Inc. ⁽¹³⁾	Surgical Devices	Equity	Preferred Series B	219,298	250	104
	Surgical Devices	Equity	Preferred Series C	656,538	282	199
	Surgical Devices	Equity	Preferred Series D	1,991,157	712	1,090
Total Gynesonics, Inc.				2,866,993	1,244	1,393
Transmedics, Inc.	Surgical Devices	Equity	Preferred Series B	88,961	1,100	402
	Surgical Devices	Equity	Preferred Series C	119,999	300	234
	Surgical Devices	Equity	Preferred Series D	260,000	650	1,129
Total Transmedics, Inc.				468,960	2,050	1,765
Subtotal: Surgical Devices (0.41%)*					3,294	3,158
Total: Equity Investments (9.49%)*					44,188	72,451

See notes to consolidated financial statements.

16

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2015

(unaudited)

(dollars in thousands)

Portfolio Company	Sub-Industry	Type of Investment ⁽¹⁾	Series	Shares	Cost ⁽²⁾	Value ⁽³⁾
Warrant Investments						
Biotechnology Tools						
Labcyte, Inc. ⁽¹³⁾	Biotechnology Tools	Warrant	Preferred Series C	1,127,624	\$ 323	\$ 425
Subtotal: Biotechnology Tools (0.06%)*					323	425
Communications & Networking						
Intelepeer, Inc. ⁽¹³⁾	Communications & Networking	Warrant	Preferred Series C	117,958	102	—
OpenPeak, Inc.	Communications & Networking	Warrant	Common Stock	108,982	149	—
PeerApp, Inc.	Communications & Networking	Warrant	Preferred Series B	298,779	61	68
Peerless Network, Inc.	Communications & Networking	Warrant	Preferred Series A	135,000	95	717
Ping Identity Corporation	Communications & Networking	Warrant	Preferred Series B	1,136,277	52	212
SkyCross, Inc. ⁽¹³⁾	Communications & Networking	Warrant	Preferred Series F	9,762,777	394	—
Spring Mobile Solutions, Inc.	Communications & Networking	Warrant	Preferred Series D	2,834,375	418	258
Subtotal: Communications & Networking (0.16%)*					1,271	1,255
Consumer & Business Products						
Antenna79 (p.k.a. Pong Research Corporation) ⁽¹³⁾	Consumer & Business Products	Warrant	Preferred Series A	1,662,441	228	36
Intelligent Beauty, Inc. ⁽¹³⁾	Consumer & Business Products	Warrant	Preferred Series B	190,234	230	284
IronPlanet, Inc.	Consumer & Business Products	Warrant	Preferred Series D	1,155,821	1,076	1,140
Market Force Information, Inc.	Consumer & Business Products	Warrant	Preferred Series A-1	150,212	24	8

Edgar Filing: HERCULES TECHNOLOGY GROWTH CAPITAL INC - Form 10-Q

The Neat Company ⁽¹³⁾	Consumer & Business Products	Warrant	Preferred Series C-1	540,540	366	356
Subtotal: Consumer & Business Products (0.24%)*					1,924	1,824
Diagnostic						
Navidea Biopharmaceuticals, Inc. (p.k.a. Neoprobe) ⁽³⁾⁽¹³⁾	Diagnostic	Warrant	Common Stock	333,333	244	28
Subtotal: Diagnostic (0.00%)*					244	28
Drug Delivery						
AcelRx Pharmaceuticals, Inc. ⁽³⁾⁽⁹⁾⁽¹³⁾	Drug Delivery	Warrant	Common Stock	176,730	786	209
Agile Therapeutics, Inc. ⁽³⁾	Drug Delivery	Warrant	Common Stock	180,274	730	686
Alexza Pharmaceuticals, Inc. ⁽³⁾	Drug Delivery	Warrant	Common Stock	37,639	645	—
BIND Therapeutics, Inc. ⁽³⁾⁽¹³⁾	Drug Delivery	Warrant	Common Stock	152,586	488	71
BioQuiddity Incorporated	Drug Delivery	Warrant	Common Stock	459,183	1	1
Celator Pharmaceuticals, Inc. ⁽³⁾	Drug Delivery	Warrant	Common Stock	210,675	138	135
Celsion Corporation ⁽³⁾	Drug Delivery	Warrant	Common Stock	194,986	428	133
Dance Biopharm, Inc. ⁽¹³⁾	Drug Delivery	Warrant	Preferred Series A	97,701	74	149
Edge Therapeutics, Inc.	Drug Delivery	Warrant	Preferred Series C-1	107,526	390	258
Egalet Corporation ⁽³⁾	Drug Delivery	Warrant	Common Stock	113,421	130	735
Kaleo, Inc. (p.k.a. Intelliject, Inc.)	Drug Delivery	Warrant	Preferred Series B	82,500	594	1,316
Neos Therapeutics, Inc. ⁽¹³⁾	Drug Delivery	Warrant	Preferred Series C	170,000	285	325
Revance Therapeutics, Inc. ⁽³⁾	Drug Delivery	Warrant	Common Stock	53,511	557	88
Zosano Pharma, Inc. ⁽³⁾	Drug Delivery	Warrant	Common Stock	31,674	164	99
Subtotal: Drug Delivery (0.55%)*					5,410	4,205

See notes to consolidated financial statements.

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2015

(unaudited)

(dollars in thousands)

Portfolio Company	Sub-Industry	Type of Investment ⁽¹⁾	Series	Shares	Cost ⁽²⁾	Value ⁽³⁾
Drug Discovery & Development						
ADMA Biologics, Inc. ⁽³⁾	Drug Discovery & Development	Warrant	Common Stock	89,750	\$295	\$278
Anthera Pharmaceuticals, Inc. ⁽³⁾⁽¹³⁾	Drug Discovery & Development	Warrant	Common Stock	40,178	984	—
Aveo Pharmaceuticals, Inc. ⁽³⁾⁽⁹⁾⁽¹³⁾	Drug Discovery & Development	Warrant	Common Stock	608,696	194	462
Cerecor Inc.	Drug Discovery & Development	Warrant	Preferred Series B	625,208	70	30
Cerulean Pharma Inc. ⁽³⁾	Drug Discovery & Development	Warrant	Common Stock	137,521	357	569
Chroma Therapeutics, Ltd. ⁽⁴⁾⁽⁹⁾	Drug Discovery & Development	Warrant	Preferred Series D	325,261	490	—
Cleveland BioLabs, Inc. ⁽³⁾⁽¹³⁾	Drug Discovery & Development	Warrant	Common Stock	7,813	105	3
Concert Pharmaceuticals, Inc. ⁽³⁾	Drug Discovery & Development	Warrant	Common Stock	70,796	367	198
Coronado Biosciences, Inc. ⁽³⁾	Drug Discovery & Development	Warrant	Common Stock	73,009	142	85
Dicerna Pharmaceuticals, Inc. ⁽³⁾⁽¹³⁾	Drug Discovery & Development	Warrant	Common Stock	200	28	—
Epirus Biopharmaceuticals, Inc. ⁽³⁾	Drug Discovery & Development	Warrant	Common Stock	64,194	276	353
Genocea Biosciences, Inc. ⁽³⁾	Drug Discovery & Development	Warrant	Common Stock	73,725	266	389
Horizon Pharma, Inc. ⁽³⁾	Drug Discovery & Development	Warrant	Common Stock	3,735	52	27
Melinta Therapeutics	Drug Discovery & Development	Warrant	Preferred Series 3	1,151,936	603	548
Nanotherapeutics, Inc. ⁽¹³⁾	Drug Discovery & Development	Warrant	Common Stock	171,389	838	1,488
Neothetics, Inc. (p.k.a. Lithera, Inc) ⁽³⁾⁽¹³⁾	Drug Discovery & Development	Warrant	Common Stock	46,838	266	133
Neuralstem, Inc. ⁽³⁾⁽¹³⁾		Warrant	Common Stock	75,187	77	44

Edgar Filing: HERCULES TECHNOLOGY GROWTH CAPITAL INC - Form 10-Q

	Drug Discovery & Development					
Paratek Pharmaceuticals, Inc. (p.k.a. Transcept Pharmaceuticals, Inc.) ⁽³⁾	Drug Discovery & Development	Warrant	Common Stock	5,121	87	5
uniQure B.V. ⁽³⁾⁽⁴⁾⁽⁹⁾	Drug Discovery & Development	Warrant	Common Stock	37,174	218	389
XOMA Corporation ⁽³⁾⁽⁹⁾⁽¹³⁾	Drug Discovery & Development	Warrant	Common Stock	181,268	279	272
Subtotal: Drug Discovery & Development (0.69%)*					5,994	5,273
Electronics & Computer Hardware						
Clustrix, Inc.	Electronics & Computer Hardware	Warrant	Common Stock	50,000	12	9
Subtotal: Electronics & Computer Hardware (0.00%)*					12	9
Energy Technology						
Agrivida, Inc. ⁽¹³⁾	Energy Technology	Warrant	Preferred Series D	471,327	120	203
Alphabet Energy, Inc. ⁽¹³⁾	Energy Technology	Warrant	Preferred Series A	86,329	81	181
American Superconductor Corporation ⁽³⁾	Energy Technology	Warrant	Common Stock	58,823	39	69
Brightsource Energy, Inc. ⁽¹³⁾	Energy Technology	Warrant	Preferred Series 1	175,000	780	185
Calera, Inc. ⁽¹³⁾	Energy Technology	Warrant	Preferred Series C	44,529	513	—
EcoMotors, Inc. ⁽¹³⁾	Energy Technology	Warrant	Preferred Series B	437,500	308	314
Fluidic, Inc.	Energy Technology	Warrant	Preferred Series D	61,804	102	44
Fulcrum Bioenergy, Inc.	Energy Technology	Warrant	Preferred Series C-1	280,897	274	186
GreatPoint Energy, Inc. ⁽¹³⁾	Energy Technology	Warrant	Preferred Series D-1	393,212	548	—
Polyera Corporation ⁽¹³⁾	Energy Technology	Warrant	Preferred Series C	311,609	337	534
SCIEnergy, Inc.	Energy Technology	Warrant	Common Stock	530,811	181	—
	Energy Technology	Warrant	Preferred Series 1	145,811	50	—
Total SCIEnergy, Inc.				676,622	231	—
Scifiniti (p.k.a. Integrated Photovoltaics, Inc.) ⁽¹³⁾	Energy Technology	Warrant	Preferred Series A-1	390,000	82	70
Solexel, Inc. ⁽¹³⁾	Energy Technology	Warrant	Preferred Series C	1,171,625	1,162	673

Edgar Filing: HERCULES TECHNOLOGY GROWTH CAPITAL INC - Form 10-Q

Stion Corporation ⁽⁵⁾	Energy Technology	Warrant	Preferred Series Seed	2,154	1,378	—
Sungevity Development, LLC	Energy Technology	Warrant	Preferred Series C	32,472,222	903	903
TAS Energy, Inc.	Energy Technology	Warrant	Preferred Series AA	428,571	299	—
TPI Composites, Inc.	Energy Technology	Warrant	Preferred Series B	160	273	201
Trilliant, Inc. ⁽¹³⁾	Energy Technology	Warrant	Preferred Series A	320,000	162	40
Subtotal: Energy Technology (0.47%)*					7,592	3,603

Healthcare Services, Other

Chromadex Corporation ⁽³⁾⁽¹³⁾	Healthcare Services, Other	Warrant	Common Stock	419,020	156	200
Subtotal: Healthcare Services, Other (0.03%)*					156	200

See notes to consolidated financial statements.

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2015

(unaudited)

(dollars in thousands)

Portfolio Company	Sub-Industry	Type of Investment ⁽¹⁾	Series	Shares	Cost ⁽²⁾	Value ⁽³⁾
Information Services						
Cha Cha Search, Inc. ⁽¹³⁾	Information Services	Warrant	Preferred Series G	48,232	\$58	\$4
INMOBI Inc. ⁽⁴⁾⁽⁹⁾	Information Services	Warrant	Common Stock	46,874	82	30
InXpo, Inc. ⁽¹³⁾	Information Services	Warrant	Preferred Series C	648,400	98	14
	Information Services	Warrant	Preferred Series C-1	740,832	59	17
Total InXpo, Inc.				1,389,232	157	31
RichRelevance, Inc. ⁽¹³⁾	Information Services	Warrant	Preferred Series E	112,612	98	—
Subtotal: Information Services (0.01%)*					395	65
Internet Consumer & Business Services						
Blurb, Inc. ⁽¹³⁾	Internet Consumer & Business Services	Warrant	Preferred Series B	218,684	299	77
	Internet Consumer & Business Services	Warrant	Preferred Series C	234,280	636	183
Total Blurb, Inc.				452,964	935	260
CashStar, Inc. ⁽¹³⁾	Internet Consumer & Business Services	Warrant	Preferred Series C-2	727,272	130	108
Gazelle, Inc. ⁽¹³⁾	Internet Consumer & Business Services	Warrant	Preferred Series A-1	991,288	158	85
Just Fabulous, Inc.	Internet Consumer & Business Services	Warrant	Preferred Series B	206,184	1,101	1,600
Lightspeed POS, Inc. ⁽⁴⁾⁽⁹⁾	Internet Consumer & Business Services	Warrant	Preferred Series C	24,561	20	68
Oportun (p.k.a. Progress Financial)	Internet Consumer & Business Services	Warrant	Preferred Series G	174,562	78	155
Prism Education Group, Inc. ⁽¹³⁾	Internet Consumer & Business Services	Warrant	Preferred Series B	200,000	43	—
Reply! Inc.		Warrant		137,225	320	—

Edgar Filing: HERCULES TECHNOLOGY GROWTH CAPITAL INC - Form 10-Q

	Internet Consumer & Business Services		Preferred Series B			
ShareThis, Inc. ⁽¹³⁾	Internet Consumer & Business Services	Warrant	Preferred Series C	493,502	547	262
Tapjoy, Inc.	Internet Consumer & Business Services	Warrant	Preferred Series D	748,670	316	102
Tectura Corporation	Internet Consumer & Business Services	Warrant	Preferred Series B-1	253,378	51	—
Subtotal: Internet Consumer & Business Services (0.35%)*					3,699	2,640

Media/Content/Info

Rhapsody International, Inc. ⁽¹³⁾	Media/Content/Info	Warrant	Common Stock	715,755	384	393
Zoom Media Group, Inc.	Media/Content/Info	Warrant	Preferred Series A	1,204	348	262
Subtotal: Media/Content/Info (0.09%)*					732	655

Medical Devices & Equipment

Amedica Corporation ⁽³⁾⁽¹³⁾	Medical Devices & Equipment	Warrant	Common Stock	516,129	459	—
Avedro, Inc. ⁽¹³⁾	Medical Devices & Equipment	Warrant	Preferred Series D	1,308,451	401	592
Aspire Bariatrics, Inc. ⁽¹³⁾	Medical Devices & Equipment	Warrant	Preferred Series D	335,000	419	426
Flowonix Medical Incorporated	Medical Devices & Equipment	Warrant	Preferred Series E	110,947	203	428
Gamma Medica, Inc.	Medical Devices & Equipment	Warrant	Preferred Series A	357,500	170	183
Gelesis, Inc. ⁽⁵⁾⁽¹³⁾	Medical Devices & Equipment	Warrant	Preferred Series A-1	263,688	78	178
Home Dialysis Plus, Inc.	Medical Devices & Equipment	Warrant	Preferred Series A	500,000	402	585
InspireMD, Inc. ⁽³⁾⁽⁴⁾⁽⁹⁾	Medical Devices & Equipment	Warrant	Common Stock	168,351	242	4
Medrobotics Corporation ⁽¹³⁾	Medical Devices & Equipment	Warrant	Preferred Series E	455,539	370	213
MELA Sciences, Inc. ⁽³⁾	Medical Devices & Equipment	Warrant	Common Stock	69,320	402	14
nContact Surgical, Inc. ⁽¹³⁾	Medical Devices & Equipment	Warrant	Preferred Series D-1	201,439	266	620
NetBio, Inc.	Medical Devices & Equipment	Warrant	Common Stock	2,568	408	56
NinePoint Medical, Inc. ⁽¹³⁾	Medical Devices & Equipment	Warrant	Preferred Series A-1	587,840	170	262
Novasys Medical, Inc.	Medical Devices & Equipment	Warrant	Common Stock	109,449	2	—
	Medical Devices & Equipment	Warrant	Preferred Series D	526,840	125	—

Edgar Filing: HERCULES TECHNOLOGY GROWTH CAPITAL INC - Form 10-Q

	Medical Devices & Equipment	Warrant	Preferred Series D-1	53,607	6	—
Total	Novasys Medical, Inc.			689,896	133	—
Optiscan Biomedical, Corp. (5)(13)	Medical Devices & Equipment	Warrant	Preferred Series D	10,535,275	1,252	278
Oraya Therapeutics, Inc.	Medical Devices & Equipment	Warrant	Common Stock	954	66	—
	Medical Devices & Equipment	Warrant	Preferred Series 1	1,632,084	676	132
Total	Oraya Therapeutics, Inc.			1,633,038	742	132
Quanterix Corporation	Medical Devices & Equipment	Warrant	Preferred Series C	115,618	156	138
SonaCare Medical, LLC (p.k.a. US HIFU, LLC)	Medical Devices & Equipment	Warrant	Preferred Series A	6,464	188	—
ViewRay, Inc. (13)	Medical Devices & Equipment	Warrant	Preferred Series C	43,103	333	316
Subtotal: Medical Devices & Equipment (0.58%)*					6,794	4,425

See notes to consolidated financial statements.

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2015

(unaudited)

(dollars in thousands)

Portfolio Company	Sub-Industry	Type of Investment ⁽¹⁾	Series	Shares	Cost ⁽²⁾	Value ⁽³⁾
Semiconductors						
Achronix Semiconductor Corporation	Semiconductors	Warrant	Preferred Series C	360,000	\$ 160	\$ 23
Aquantia Corp.	Semiconductors	Warrant	Preferred Series G	196,831	4	3
Avnera Corporation	Semiconductors	Warrant	Preferred Series E	102,958	14	34
Subtotal: Semiconductors (0.01%)*					178	60
Software						
Atrenta, Inc.	Software	Warrant	Preferred Series D	392,670	120	432
Braxton Technologies, LLC	Software	Warrant	Preferred Series A	168,750	188	—
CareCloud Corporation ⁽¹³⁾	Software	Warrant	Preferred Series B	413,433	258	452
Clickfox, Inc. ⁽¹³⁾	Software	Warrant	Preferred Series B	1,038,563	330	990
	Software	Warrant	Preferred Series C	592,019	730	676
	Software	Warrant	Preferred Series C-A	46,109	13	44
Total Clickfox, Inc.				1,676,691	1,073	1,710
Daegis Inc. (p.k.a. Unify Corporation) ⁽³⁾ ⁽¹³⁾	Software	Warrant	Common Stock	718,860	1,434	3
Hillcrest Laboratories, Inc. ⁽¹³⁾	Software	Warrant	Preferred Series E	1,865,650	55	123
JumpStart Games, Inc. (p.k.a. Knowledge Holdings, Inc.) ⁽¹³⁾	Software	Warrant	Preferred Series E	614,333	16	8
Message Systems, Inc. ⁽¹³⁾	Software	Warrant	Preferred Series B	408,011	334	330
Mobile Posse, Inc. ⁽¹³⁾	Software	Warrant	Preferred Series C	396,430	130	58

Edgar Filing: HERCULES TECHNOLOGY GROWTH CAPITAL INC - Form 10-Q

Neos Geosolutions, Inc. ⁽¹³⁾	Software	Warrant	Preferred Series 3	221,150	22	—
NewVoiceMedia Limited ⁽⁴⁾⁽⁹⁾	Software	Warrant	Preferred Series E	225,586	33	71
Poplicus Incorporated ⁽¹³⁾	Software	Warrant	Preferred Series B-1	2,595,230	—	87
Soasta, Inc. ⁽¹³⁾	Software	Warrant	Preferred Series E	410,800	691	717
Sonian, Inc. ⁽¹³⁾	Software	Warrant	Preferred Series C	185,949	106	65
StrongView Systems, Inc.	Software	Warrant	Preferred Series C	551,470	168	227
SugarSync, Inc. ⁽¹³⁾	Software	Warrant	Preferred Series CC	332,726	78	102
	Software	Warrant	Preferred Series DD	107,526	34	34
Total SugarSync, Inc.				440,252	112	136
Touchcommerce, Inc. ⁽¹³⁾	Software	Warrant	Preferred Series E	1,885,930	361	282
White Sky, Inc. ⁽¹³⁾	Software	Warrant	Preferred Series B-2	124,295	54	6
Subtotal: Software (0.62%)*					5,155	4,707
Specialty Pharmaceuticals						
Alimera Sciences, Inc. ⁽³⁾	Specialty Pharmaceuticals	Warrant	Common Stock	285,016	729	521
QuatRx Pharmaceuticals Company	Specialty Pharmaceuticals	Warrant	Preferred Series E	155,324	307	—
Subtotal: Specialty Pharmaceuticals (0.17%)*					1,036	521

See notes to consolidated financial statements.

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2015

(unaudited)

(dollars in thousands)

Portfolio Company	Sub-Industry	Type of Investment ⁽¹⁾	Series	Shares	Cost ⁽²⁾	Value ⁽³⁾
Surgical Devices						
Gynesonics, Inc. ⁽¹³⁾	Surgical Devices	Warrant	Preferred Series C	180,480	\$75	\$50
	Surgical Devices	Warrant	Preferred Series D	1,575,965	320	585
Total Gynesonics, Inc.				1,756,445	395	635
Transmedics, Inc.	Surgical Devices	Warrant	Preferred Series B	40,436	224	4
	Surgical Devices	Warrant	Preferred Series D	175,000	100	404
Total Transmedics, Inc.				215,436	324	408
Subtotal: Surgical Devices (0.14%)*					719	1,043
Total Warrant Investments (4.05%)*					41,634	30,938
Total Investments (152.15%)*					\$1,170,808	\$1,161,421

* Value as a percent of net assets

- (1) Preferred and common stock, warrants, and equity interests are generally non-income producing.
- (2) Gross unrealized appreciation, gross unrealized depreciation, and net depreciation for federal income tax purposes totaled \$50.4 million, \$60.9 million and \$10.5 million respectively. The tax cost of investments is \$1.2 billion.
- (3) Except for warrants in 33 publicly traded companies and common stock in 14 publicly traded companies, all investments are restricted at March 31, 2015 and were valued at fair value as determined in good faith by the Audit Committee of the Board of Directors. No unrestricted securities of the same issuer are outstanding. The Company uses the Standard Industrial Code for classifying the industry grouping of its portfolio companies.
- (4) Non-U.S. company or the company's principal place of business is outside the United States.
- (5) Affiliate investment that is defined under the Investment Company Act of 1940 as companies in which HTGC owns at least 5% but not more than 25% of the voting securities of the company.
- (6) Control investment that is defined under the Investment Company Act of 1940 as companies in which HTGC owns at least 25% of the voting securities of the company or has greater than 50% representation on its board. There were no control investments at March 31, 2015.
- (7) Debt is on non-accrual status at March 31, 2015, and is therefore considered non-income producing.
- (8) Denotes that all or a portion of the debt investment is convertible senior debt.
- (9) Indicates assets that the Company deems not "qualifying assets" under section 55(a) of the Investment Company Act of 1940, as amended. Qualifying assets must represent at least 70% of the Company's total assets at the time of acquisition of any additional non-qualifying assets.
- (10) Denotes that all or a portion of the debt investment secures the notes offered in the Debt Securitizations (as defined in Note 4).
- (11)

Denotes that all or a portion of the debt investment principal includes accumulated PIK, or payment-in-kind, interest and is net of repayments.

(12) Denotes that all or a portion of the debt investment includes an exit fee receivable.

(13) Denotes that all or a portion of the investment in this portfolio company is held by HT II or HT III, the Company's wholly-owned SBIC subsidiaries.

(14) The stated 'Maturity Date' for the Tectura assets reflects the last extension of the forbearance period on these loans. The borrower loans remain outstanding and management is continuing to work with the borrower to satisfy the obligations. The Company's investment team and Investment Committee continue to closely monitor developments at the borrower company.

See notes to consolidated financial statements.

21

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2014

(dollars in thousands)

Portfolio Company	Sub-Industry	Type of Investment ⁽¹⁾	Maturity Date	Interest Rate and Floor	Principal Amount	Cost ⁽²⁾	Value
Biotechnology Tools							
1-5 Years Maturity							
Genzyme, Inc. (12)(13)	Biotechnology Tools	Senior Secured	June 2016	Interest rate PRIME + 6.70% or Floor rate of 9.95%	\$2,695	\$2,869	\$2,869
Total: 1-5 Years Maturity						2,869	2,869
Total: Biotechnology Tools (0.44%)*						2,869	2,869
Communications & Networking							
1-5 Years Maturity							
Peak Performance (10)(12)	Communications & Networking	Senior Secured	April 2017	Interest rate PRIME + 8.75% or Floor rate of 12.00%	\$12,889	13,193	13,193
CrossLink (12)(13)	Communications & Networking	Senior Secured	January 2018	Interest rate PRIME + 9.70% or Floor rate of 12.95%	\$22,000	21,580	20,100
VeriSign Mobile Solutions, (10)(12)	Communications & Networking	Senior Secured	November 2016	Interest rate PRIME + 8.00% or Floor rate of 11.25%	\$18,840	18,928	19,100
Total: 1-5 Years Maturity						53,701	52,400
Total: Communications & Networking (6%)*						53,701	52,400
Consumer & Business Products							
1-5 Years Maturity							
Anna's a. Pong Research Corporation) (13)	Consumer & Business Products	Senior Secured	December 2017	Interest rate PRIME + 6.75% or Floor rate of 10.00%	\$5,000	4,912	4,880
	Consumer & Business Products	Senior Secured	June 2016	Interest rate PRIME + 6.75%	\$216	89	89

					or Floor rate of 10.00%		
al Antenna79 (p.k.a. Pong Research Corporation)					\$5,216	5,001	4,97
, Inc. (8)	Consumer & Business Products	Convertible Senior Note	March 2017	Interest rate FIXED 4.00%	\$100	100	100
Planet, (12)	Consumer & Business Products	Senior Secured	November 2017	Interest rate PRIME + 6.20%			
				or Floor rate of 9.45%	\$37,500	36,345	36,3
Neat npany (12)(13)	Consumer & Business Products	Senior Secured	September 2017	Interest rate PRIME + 7.75%			
				or Floor rate of 11.00%,			
				PIK Interest 1.00%	\$20,061	19,422	19,4
total: 1-5 Years Maturity						60,868	60,8
total: Consumer & Business Products							
(3%)*						60,868	60,8

See notes to consolidated financial statements.

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2014

(dollars in thousands)

Portfolio Company	Sub-Industry	Type of Investment ⁽¹⁾	Maturity Date	Interest Rate and Floor	Principal Amount	Cost ⁽²⁾	Value ⁽³⁾
Drug Delivery							
Under 1 Year Maturity							
Revanche Therapeutics, Inc. ⁽¹⁰⁾⁽¹²⁾	Drug Delivery	Senior Secured	March 2015	Interest rate PRIME + 6.60%			
				or Floor rate of 9.85%	\$2,098	\$2,458	\$2,458
	Drug Delivery	Senior Secured	March 2015	Interest rate PRIME + 6.60%			
				or Floor rate of 9.85%	\$210	246	246
Total Revance Therapeutics, Inc.					\$2,308	2,704	2,704
Subtotal: Under 1 Year Maturity						2,704	2,704
1-5 Years Maturity							
AcelRx Pharmaceuticals, Inc. ⁽⁹⁾⁽¹⁰⁾⁽¹²⁾⁽¹³⁾	Drug Delivery	Senior Secured	October 2017	Interest rate PRIME + 3.85%			
				or Floor rate of 9.10%	\$25,000	24,831	24,969
BIND Therapeutics, Inc. ⁽¹²⁾⁽¹³⁾	Drug Delivery	Senior Secured	September 2016	Interest rate PRIME + 7.00%			
				or Floor rate of 10.25%	\$3,274	3,343	3,228
BioQuiddity Incorporated ⁽¹²⁾	Drug Delivery	Senior Secured	May 2018	Interest rate PRIME + 8.00%			
				or Floor rate of 11.25%	\$7,500	7,439	7,439
Celator Pharmaceuticals,	Drug Delivery	Senior Secured	June 2018	Interest rate PRIME + 6.50%	\$10,000	9,927	9,899

Edgar Filing: HERCULES TECHNOLOGY GROWTH CAPITAL INC - Form 10-Q

Inc. ⁽¹⁰⁾⁽¹²⁾				or Floor rate of 9.75%			
Celsion Corporation ⁽¹⁰⁾⁽¹²⁾	Drug Delivery	Senior Secured	June 2017	Interest rate PRIME + 8.00%			
				or Floor rate of 11.25%	\$ 10,000	9,858	10,027
Dance Biopharm, Inc. ⁽¹²⁾⁽¹³⁾	Drug Delivery	Senior Secured	November 2017	Interest rate PRIME + 7.40%			
				or Floor rate of 10.65%	\$ 3,905	3,871	3,864
Edge Therapeutics, Inc. ⁽¹²⁾	Drug Delivery	Senior Secured	March 2018	Interest rate PRIME + 5.95%			
				or Floor rate of 10.45%	\$ 3,000	2,847	2,847
Neos Therapeutics, Inc. ⁽¹²⁾⁽¹³⁾	Drug Delivery	Senior Secured	October 2017	Interest rate PRIME + 7.25%			
				or Floor rate of 10.50%	\$ 5,000	4,916	4,916
	Drug Delivery	Senior Secured	October 2017	Interest rate FIXED 9.00%	\$ 10,000	10,010	10,063
Total Neos Therapeutics, Inc.					\$ 15,000	14,926	14,979
Zosano Pharma, Inc. ⁽¹⁰⁾⁽¹²⁾	Drug Delivery	Senior Secured	June 2017	Interest rate PRIME + 6.80%			
				or Floor rate of 12.05%	\$ 4,000	3,894	3,881
Subtotal: 1-5 Years Maturity						80,936	81,133
Subtotal: Drug Delivery (12.72%)*						83,640	83,837

See notes to consolidated financial statements.

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2014

(dollars in thousands)

Company	Sub-Industry	Type of Investment ⁽¹⁾	Maturity Date	Interest Rate and Floor	Principal Amount	Cost ⁽²⁾
Under 1 Year Maturity						
Company	Drug Discovery & Development	Senior Secured	December 2015	Interest rate PRIME + 7.15%		
				or Floor rate of 11.90%	\$11,611	\$11,611
Pharmaceuticals, (13)	Drug Discovery & Development	Senior Secured	October 2015	Interest rate PRIME + 3.25%		
				or Floor rate of 8.50%	\$7,175	7,142
Under 1 Year Maturity						
Company	Drug Discovery & Development	Senior Secured	December 2017	Interest rate PRIME + 5.5%		
				or Floor rate of 8.75%,		
				PIK Interest 1.95%	\$5,000	4,879
Pharmaceuticals, (13)	Drug Discovery & Development	Senior Secured	December 2017	Interest rate PRIME + 3.00%		
				or Floor rate of 8.75%,		
				PIK Interest 1.95%	\$10,153	10,032
Pharmaceuticals, (13)	Drug Discovery & Development	Senior Secured	January 2018	Interest rate PRIME + 6.65%		
				or Floor rate of 11.90%	\$10,000	9,766
Pharmaceuticals, (12)(13)	Drug Discovery & Development	Senior Secured	February 2018	Interest rate PRIME + 5.00%		
				or Floor rate of 8.25%	\$10,000	10,022
Pharmaceuticals, (10)(12)	Drug Discovery & Development	Senior Secured	April 2018	Interest rate PRIME + 6.30%		
				or Floor rate of 9.55%	\$18,000	18,020
Pharmaceuticals, (12)	Drug Discovery & Development	Senior Secured	August 2017	Interest rate PRIME + 6.30%		
				or Floor rate of 9.55%	\$7,500	7,374
Pharmaceuticals, (12)	Drug Discovery & Development	Senior Secured	January 2017	Interest rate PRIME + 6.10%		
				or Floor rate of 9.35%	\$1,883	1,883

Edgar Filing: HERCULES TECHNOLOGY GROWTH CAPITAL INC - Form 10-Q

Pharma Corp. (pka eutics,	Drug Discovery & Development	Senior Secured	October 2016	Interest rate PRIME + 6.75%		
				or Floor rate of 10.00%	\$4,584	4,584
	Drug Discovery & Development	Senior Secured	October 2016	Interest rate PRIME + 9.00%		
				or Floor rate of 12.25%	\$13,890	13,890
BioPharma Corp. (pka Cell Therapeutics, Inc.)					\$18,474	18,474
Technologies	Drug Discovery & Development	Senior Secured	July 2018	Interest rate PRIME + 6.50%		
				or Floor rate of 9.75%	\$10,000	9,897
pharmaceuticals,	Drug Discovery & Development	Senior Secured	April 2018	Interest rate PRIME + 4.70%		
				or Floor rate of 7.95%	\$7,500	7,308
sciences, Inc.	Drug Discovery & Development	Senior Secured	July 2018	Interest rate PRIME + 2.25%		
				or Floor rate of 7.25%	\$12,000	11,814
orporated ⁽¹⁰⁾⁽¹²⁾	Drug Discovery & Development	Senior Secured	January 2018	Interest rate PRIME + 4.75%		
				or Floor rate of 9.25%	\$25,000	24,854
erapeutics ⁽¹²⁾	Drug Discovery & Development	Senior Secured	June 2018	Interest rate PRIME + 5.00%		
				or Floor rate of 8.25%	\$20,000	19,272
icals, Inc. ⁽¹²⁾	Drug Discovery & Development	Senior Secured	November 2016	Interest rate PRIME + 5.30%		
				or Floor rate of 10.55%	\$40,000	40,578
Inc. (pka) ⁽¹²⁾⁽¹³⁾	Drug Discovery & Development	Senior Secured	January 2018	Interest rate PRIME + 5.75%		
				or Floor rate of 9.00%	\$10,000	9,751
, Inc. ⁽¹²⁾⁽¹³⁾	Drug Discovery & Development	Senior Secured				